GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Total Liabilities

Biomarin Pharmaceutical (MIL:1BMRN) Total Liabilities : €1,655 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Total Liabilities?

Biomarin Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 was €1,655 Mil.

Biomarin Pharmaceutical's quarterly Total Liabilities declined from Sep. 2023 (€1,744.01 Mil) to Dec. 2023 (€1,733.18 Mil) and declined from Dec. 2023 (€1,733.18 Mil) to Mar. 2024 (€1,654.95 Mil).

Biomarin Pharmaceutical's annual Total Liabilities increased from Dec. 2021 (€1,539.11 Mil) to Dec. 2022 (€1,672.69 Mil) and increased from Dec. 2022 (€1,672.69 Mil) to Dec. 2023 (€1,733.18 Mil).


Biomarin Pharmaceutical Total Liabilities Historical Data

The historical data trend for Biomarin Pharmaceutical's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Total Liabilities Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,410.89 1,431.94 1,539.11 1,672.69 1,733.18

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,657.53 1,643.26 1,744.01 1,733.18 1,654.95

Biomarin Pharmaceutical Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biomarin Pharmaceutical's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1079.331+(543.868+109.981
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1,733

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=6273.75-4540.57
=1,733

Biomarin Pharmaceutical's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1000.868+(546.117+107.963
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1,655

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=6322.859-4667.911
=1,655

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines